Laurel Wealth Planning’s GSK GSK Stock Holding History

Laurel Wealth Planning’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-187	Closed	-$8K	–	126
2020 Q4	$8K	Buy	+187	New	+$8.59K	0.01%	86

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Laurel Wealth Planning's GSK Position: Q1 2021 in Review

Laurel Wealth Planning sold out of GSK (GSK) in Q1 2021, closing a stake of 187 shares — an estimated $8K sold.

Laurel Wealth Planning first reported a position in GSK in Q4 2020 and held it in 1 quarter. The position peaked at $8K in Q4 2020. 774 funds tracked by Wall St. Rank hold GSK as of Q1 2021.

Laurel Wealth Planning reported no remaining GSK position as of Q1 2021 after selling out during the quarter.
Laurel Wealth Planning sold 187 GSK shares in Q1 2021, an estimated $8K.
Laurel Wealth Planning first reported a position in GSK in Q4 2020 and held it in 1 quarter.
Laurel Wealth Planning's GSK position peaked at $8K in Q4 2020.
774 funds tracked by Wall St. Rank held GSK as of Q1 2021.

Based on Laurel Wealth Planning's 13F filing for Q1 2021, filed 6 May 2021.